IMRT Combined with Lobaplatin-based CCRT in Nasopharyngeal Carcinoma

Launched by THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIVERSITY · Nov 12, 2024

Keywords

ClinConnect Summary

Lobaplatin, as a third-generation platinum-based chemotherapeutic agent, demonstrates equivalent therapeutic efficacy to cisplatin but significantly lower toxicity. Preliminary clinical trials have confirmed that lobaplatin shows substantial effectiveness in treating various cancers including breast cancer, esophageal cancer, colorectal cancer, and cervical cancer. Importantly, lobaplatin does not exhibit cross-resistance with cisplatin or carboplatin, indicating a promising application prospect.

Currently, lobaplatin has demonstrated clear efficacy in non-elderly nasopharyngeal carcinoma ...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Pathologically confirmed differentiated non-keratinizing carcinoma and undifferentiated non-keratinizing carcinoma;
• • Stage II-IVa (UICC 8th edition);
• • Acceptable induction chemotherapy and Tarceva targeted therapy;
• • No history of other malignant tumors;
• • Male or female, aged 65-80 years.
• • Liver function: Total bilirubin ≤ Upper Limit of Normal (ULN); AST and ALT ≤ 2.5 times ULN; Alkaline phosphatase ≤ 5 times ULN;
• • Renal function: Creatinine clearance ≥ 60 ml/min or Creatinine ≤ 1.5 × ULN;
• • Hematological tests: Absolute Neutrophil Count (ANC) ≥ 2 × 10\^9/L, Platelet count ≥ 100 × 10\^9/L, and Hemoglobin ≥ 9 g/dL;
• • No severe dysfunction of vital organs such as heart and lung;
• • PS score ≤ 2 points
• Exclusion Criteria:
• • Distant metastases detected before treatment;
• • Refusal to sign the informed consent form;
• • Patients who cannot comply with regular follow-up due to psychological, social, family, or geographical reasons;
• • Simultaneously receiving other experimental treatments in clinical trials (during the treatment phase of clinical research);
• • Severe, uncontrolled infections or medical conditions;
• • Vital organ dysfunction, decompensated heart, lung, kidney, or liver failure, unable to tolerate radiotherapy and chemotherapy;
• • Laboratory tests: Total bilirubin \> Upper Limit of Normal (ULN); AST and/or ALT \> 1.5 times ULN with alkaline phosphatase \> 2.5 times ULN;
• • Factors affecting drug administration, distribution, metabolism, and excretion, such as mental abnormalities, central nervous system abnormalities, chronic diarrhea, ascites, pleural effusion, etc.;
• • Long-term use of immunosuppressants after organ transplantation;
• • Patients with a history of other malignant tumors before enrollment.